December 19, 2025/
This document is an official guidance from the U.S. Food and Drug Administration (FDA) issued in December 2025. It provides the agency's current recommendations and interpretations on how clinical...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
This document is an official guidance from the U.S. Food and Drug Administration (FDA) issued in December 2025. It provides the agency's current recommendations and interpretations on how clinical...
Adverse Childhood Experiences (ACEs) are potentially traumatic events occurring before the age of 18. These experiences range from direct personal harm to environmental instability. The term...
This is a master research protocol published by the World Health Organization (WHO) in 2025. Its primary purpose is to provide a standardized, ready-to-use blueprint for countries—particularly low- and...
